RxDoctor Payments Data

Samuel Dunn, MD

Gastroenterology · North Little Rock, ARNPI 1689038416

Payments from drug & device makers

$3,203in general payments, 2019–2025

Across 174 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Braintree Laboratories, Inc.$456
  • Johnson & Johnson$301
  • Takeda Pharmaceuticals U.S.A., Inc.$246
  • Boston Scientific$219
  • Regeneron Healthcare Solutions, Inc.$174
  • plus $795 from 11 others

What the payments were for

  • Food & beverage$2,78987%
  • Education$90%
  • Gifts$40513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,203 in reported general payments places this provider in the 35th percentile of 108 gastroenterology providers in Arkansas.

See all gastroenterology providers in Arkansas

Medicare billing

Part B allowed, 2024
$191,253
Medicare patients
620
Services billed
2,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$401,118
Entyvio PenVedolizumab12$70,425
LinzessLinaclotide57$38,319
Budesonide DrBudesonide13$4,548
Colestipol Hcl78$3,395
SutabSod Sulf/Pot Chloride/Mag Sulf20$3,241
Pantoprazole Sodium248$2,772
Balsalazide Disodium16$2,689
Omeprazole227$2,381
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl149$2,256
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl141$2,240
Azathioprine20$876
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg28$782
Ondansetron OdtOndansetron26$601
Sucralfate30$522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$301$401,11815 claims
AbbVieLinzess$1,011$38,31957 claims
Braintree Laboratories, Inc.Sutab$456$3,24120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 108 gastroenterology providers in Arkansas.

Other gastroenterology in North Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →